About: Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $41.09 (-5.04%)
VCEL NASDAQ Vericel Corp Ord
Vericel Corp Ord share price
Atividade de preço de VCEL
Último preço
$ 41,090
Variação (24h)
-2,18 USD (5,04%)
Volume
677.59K
Volume (média 4 sem.)
-
Abertura
$ 43,05
Variação do dia
$ 40,59 - $ 43,50
Fechamento anterior
$ 43,27
Último negócio
28 Oct, 8:00 pm GMT+0
Atrasado
28 Oct, 8:00 pm GMT+0
VCEL price performance
Atrasado
28 Oct, 8:00 pm GMT+0
quote.marketSignals